Advertisement
Table 1 Baseline patient characteristics
| Arm A (n = 18) | Arm B (n = 24) | p-value | |
|---|---|---|---|
| Clinical characteristics | |||
| Female: n (%) | 13 (72.2) | 19 (79.2) | – |
| Age: median (range) | 63 (24–80) | 65.5 (27–82) | – |
| Radio-induced: n (%) | 7 (38.9) | 12 (50) | – |
| Superficial: n (%)a | 11 (61.1) | 16 (66.7) | – |
| Grade 2 or 3: n (%) | 10 (55.6) | 13 (54.2) | – |
| Metastatic: n (%) | 12 (66.7) | 16 (66.7) | – |
| Prior exposure to anthracycline: n (%) | 8 (44.4) | 8 (33.3) | – |
| Performance status (WHO) = 0: n (%)b | 10 (58.8) | 13 (54.2) | – |
| Baseline biomarkers (D1) | |||
| Human FGF (pg/mL): mean (sd) | 5.6 (2.1) | 6.0 (3.5) | 0.72 |
| PlGF (pg/mL): mean (sd) | 24.7 (17.2) | 17.8 (10.2) | 0.12 |
| SCF sR/c-kit (ng/mL): mean (sd) | 8.9 (2.5) | 8.2 (2.6) | 0.35 |
| sE-Selectin (ng/mL): mean (sd) | 33.7 (18.5) | 44.8 (24.9) | 0.08 |
| TSP-1 (μg/mL): mean (sd) | 54.9 (17.3) | 44.9 (21.6) | 0.17 |
| VEGF (ng/mL): mean (sd) | 0.44 (0.28) | 0.55 (0.39) | 0.38 |
| VEGF-C (ng/mL): mean (sd) | 4.2 (1.5) | 4.4 (1.7) | 0.70 |
